MedTrace Logo

An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial

NCT00872963 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2015-12-07

No results posted yet for this study

Summary

Malaria is one of the leading causes of deaths in children below five years old. Despite antimalarial drugs and insecticide treated bed nets, the established means of treatment and protection, malaria still continues to affect many children. A malaria vaccine would be a very effective way of reducing malaria infection in the community. RTS,S/AS01E is a leading malaria vaccine candidate which is being developed for children in Africa. The investigators have done a study to find out if this vaccine is effective in reducing infection by malaria in children aged 5-17 months living in Kenya and Tanzania. The follow up of the original study was 14-18 months. The extended follow up is proposed to continue for another four years.

Conditions

Interventions

BIOLOGICAL

RTS,S/AS01E

0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • KEMRI-Wellcome Trust Collaborative Research Program

    lead OTHER

Principal Investigators

  • Ally Olotu · KEMRI-Wellcome Trust Collaborative Research Program

Eligibility

Min Age
19 Months
Max Age
35 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2016-02-29
Completion
2016-08-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00872963 on ClinicalTrials.gov